BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu F, Wang KY, Wang N, Li G, Liu D. Bioactivity of a modified human Glucagon-like peptide-1. PLoS One 2017;12:e0171601. [PMID: 28152036 DOI: 10.1371/journal.pone.0171601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 He S, Zhang J, Wang T, Wu P, Liu J, Li M, Ma B. The Biological Role of Optimized Recombinant Oral Long-Acting Glucagon Like Peptide-1 and Its Impact on the Expression of Genes Associated with Glucose Metabolism of Diabetes. Int J Pept Res Ther 2021;27:745-54. [DOI: 10.1007/s10989-020-10123-6] [Reference Citation Analysis]
2 Ismail R, Bocsik A, Katona G, Gróf I, Deli MA, Csóka I. Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability. Pharmaceutics 2019;11:E599. [PMID: 31726699 DOI: 10.3390/pharmaceutics11110599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Xu F, Wang KY, Wang N, Li G, Liu D. Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice. PLoS One 2017;12:e0181939. [PMID: 28750064 DOI: 10.1371/journal.pone.0181939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Lobaton-Ginsberg M, Sotelo-González P, Ramirez-Renteria C, Juárez-Aguilar FG, Ferreira-Hermosillo A. Insulinoma after sleeve gastrectomy: A case report. World J Clin Cases 2022; 10(18): 6227-6233 [DOI: 10.12998/wjcc.v10.i18.6227] [Reference Citation Analysis]